Heterologous protein exposure and secretion optimization in Mycoplasma pneumoniae

Ana, Yamile; Gerngross, Daniel; Serrano Pubull, Luis, 1982-

doi:http://dx.doi.org/10.1186/s12934-024-02574-z

Heterologous protein exposure and secretion optimization in Mycoplasma pneumoniae

License

Citation

Ana Y, Gerngross D, Serrano L. Heterologous protein exposure and secretion optimization in Mycoplasma pneumoniae. Microb Cell Fact. 2024 Nov 13;23(1):306. DOI: 10.1186/s12934-024-02574-z

Abstract

The non-pathogenic Mycoplasma pneumoniae engineered chassis (Mycochassis) has demonstrated the ability to express therapeutic molecules in vitro and to be effective for treatment of lung infectious diseases in in vivo mouse models. However, the expression of heterologous molecules, whether secreted or exposed on the bacterial membrane has not been optimized to ensure sufficient secretion and/or exposure levels to exert a maximum in vivo biological effect. Here, we have improved the currently used secretion signal from MPN142 protein. We found that mutations at P1' position of the signal peptide cleavage site do not abrogate secretion but affect it. Increasing hydrophobicity and mutations at the C-terminal of the signal peptide increases secretion. We tested different lipoprotein signal peptides as possible N-terminal protein anchoring motifs on the Mpn cell surface. Unexpectedly we found that these peptides exhibit variable retention and secretion rates of the protein, with some sequences behaving as full secretion motifs. This raises the question of the biological role of the lipobox motif traditionally thought to anchor membrane proteins without a helical transmembrane domain. These results altogether represent a step forward in chassis optimization, offering different sequences for secretion or membrane retention, which could be used to improve Mycochassis as a delivery vector, and broadening its therapeutic possibilities.